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Background: Understanding the molecular mechanisms involved in disease is critical for the development of more
effective and individualized strategies for prevention and treatment. The amount of disease-related literature, including
new genetic information on the molecular mechanisms of disease, is rapidly increasing. Extracting beneficial information
from literature can be facilitated by computational methods such as the knowledge-discovery approach. Several
methods for mining gene-disease relationships using computational methods have been developed, however, there
has been a lack of research evaluating specific disease candidate genes.
Results: We present a novel method for gathering and prioritizing specific disease candidate genes. Our approach
involved the construction of a set of Medical Subject Headings (MeSH) terms for the effective retrieval of publications
related to a disease candidate gene. Information regarding the relationships between genes and publications was
obtained from the gene2pubmed database. The set of genes was prioritized using a “weighted literature score” based
on the number of publications and weighted by the number of genes occurring in a publication. Using our method for
the disease states of pain and Alzheimer’s disease, a total of 1101 pain candidate genes and 2810 Alzheimer’s disease
candidate genes were gathered and prioritized. The precision was 0.30 and the recall was 0.89 in the case study of pain.
The precision was 0.04 and the recall was 0.6 in the case study of Alzheimer’s disease. The precision-recall curve indicated
that the performance of our method was superior to that of other publicly available tools.
Conclusions: Our method, which involved the use of a set of MeSH terms related to disease candidate genes and a
novel weighted literature score, improved the accuracy of gathering and prioritizing candidate genes by focusing on a
specific disease.Background
Understanding the molecular mechanisms involved in
disease is critical for the development of more effective
and individualized strategies for prevention and treat-
ment. At present, there are several strategies available
for gathering appropriate information about the molecu-
lar mechanisms of disease from a genetic point of view.
One of these strategies is to search specific disease-
related gene databases [1,2]. As these databases are built
based on manual processes, the data quality is high.
However, owing to high manpower costs, it is difficult to* Correspondence: kuhara@grt.kyushu-u.ac.jp
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growing new literatures.
The other strategy is to use bioinformatics methods to
extract and prioritize disease candidate genes automatic-
ally [3,4]. These methods have been classified into sev-
eral categories, such as text mining and integration of
multiple data sources. Text mining methods have been
particularly well studied in the biological field, because
scientific literature represents a rich source for mining-
based retrieval of information on gene-disease relation-
ships. Some methods for extracting knowledge from
literature are based on keyword co-occurrence analysis
and the automatic extraction of entity names from text
[5]. The ranking method of gene prioritization is based
on the co-occurrence of query terms, association words,
and database terms, and a rule-based pattern recognitiontral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Lists of a) gene ontology terms and b)
mammalian phenotype terms that were used to create
pain gene set 1
ID Term
a)
GO:0019233 Sensory perception of pain
GO:0050968 Detection of chemical stimulus involved
in sensory perception of pain
GO:0050967 Detection of electrical stimulus involved
in sensory perception of pain
GO:0050966 Detection of mechanical stimulus involved
in sensory perception of pain
GO:0050965 Detection of temperature stimulus involved
in sensory perception of pain
GO:0051930 Regulation of sensory perception of pain
GO:0044465 Modulation of sensory perception of pain
in another organism
GO:0019234 Sensory perception of fast pain
GO:0019235 Sensory perception of slow pain
GO:0048265 Response to pain
GO:0048266 Behavioral response to pain
GO:0061366 Behavioral response to chemical pain
GO:0061367 Behavioral response to acetic acid induced pain
GO:0061368 Behavioral response to formalin induced pain
b)
MP:0001491 Unresponsive to tactile stimuli
MP:0001968 Abnormal touch/nociception
MP:0001970 Abnormal pain threshold
MP:0001973 Increased thermal nociceptive threshold
MP:0001980 Abnormal chemically-elicited antinociception
MP:0001981 Increased chemically-elicited antinociception
MP:0001982 Decreased chemically-elicited antinociception
MP:0002733 Abnormal thermal nociception
MP:0002734 Abnormal mechanical nociception
MP:0002735 Abnormal chemical nociception
MP:0002736 Abnormal nociception after inflammation
MP:0002738 Hyperresponsive to tactile stimuli
MP:0003043 Hypoalgesia
MP:0003177 Allodynia
MP:0003998 Decreased thermal nociceptive threshold
MP:0004270 Analgesia
MP:0005316 Abnormal response to tactile stimuli
MP:0005407 Hyperalgesia
MP:0005498 Hyporesponsive to tactile stimuli
MP:0008531 Increased chemical nociceptive threshold
MP:0008532 Decreased chemical nociceptive threshold
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[6] and LEGENDA [7]. In addition, methods to extract
and prioritize candidate genes based on multiple data
sources, such as sequence-based features, annotation
data and GWAS data, have been proposed. Examples of
these tools include Genotator [8] and Gene Prospector
[9]. While several attempts have been made to compre-
hensively extract and prioritize candidate disease genes
by using bioinformatics techniques, a methodology for
determining specific disease-relevant genes, such as pain,
has not yet been fully developed [10].
The aim of our study was to develop a semi-automated
method of gathering and prioritization of specific disease-
related genes using a specialist’s knowledge that is GO and
MP term selection. In this study, our approach has been
applied to pain disease. In addition, we conducted a gene
search related to Alzheimer’s disease (AD) to evaluate the
application of this method to other specific disease. There
are significant unmet medical needs in both diseases. To
understand the underlying molecular mechanism is im-
portant to develop the new treatment and drug.
Our method involved the following: avoiding errors
associated with gene name recognition using the gene2-
pubmed database [11], which links to PubMed® literature
related to the gene, improving information retrieval from
PubMed by creating a set of pain-related MeSH terms,
and improving the prioritization accuracy with a novel
score based on the number of publications. The priority
score is weighted by the number of genes occurring in a
publication. The performance of our method was com-
pared to those of other publicly available tools. We will




Literature data available in July 2012 was obtained from
the NLM (National Library of Medicine). MeSH terms
were also obtained from NLM (http://www.nlm.nih.gov/
mesh/meshhome.html). GO terms [12] were downloaded
from the Gene Ontology Consortium web site (http://
www.geneontology.org/). Mammalian phenotype (MP)
terms [13] were downloaded from the Mouse Genome In-
formatics (MGI) website (http://www.informatics.jax.org/
searches/MP_form.shtml). The list of pain-related genes
was downloaded from the Pain Gene Database website
(http://www.jbldesign.com/jmogil/enter.html) [14]. The list
of AD-related genes was constructed from OMIM and
KEGG database [15,16].
Validation sets
Two sets of disease-related genes were generated to as-
sess the performance of the method for each disease,
those were pain and AD. The first set, gene set 1, was
Table 2 Lists of a) gene ontology terms and b)
mammalian phenotype terms that were used to create





GO:0034231 Slet amyloid polypeptide processing
GO:0042982 Amyloid precursor protein metabolic process
GO:0042983 Amyloid precursor protein biosynthetic process
GO:0042984 Regulation of amyloid precursor
protein biosynthetic process
GO:0042987 Amyloid precursor protein catabolic process
GO:0044548 S100 protein binding
GO:0048152 S100 beta biosynthetic process
GO:0048153 S100 alpha biosynthetic process
GO:0048156 Tau protein binding
GO:0050435 Beta-amyloid metabolic process
GO:0097242 Beta-amyloid clearance
GO:1900221 Regulation of beta-amyloid clearance
GO:1902003 Regulation of beta-amyloid formation
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MeSH terms and prioritizing score. The other set, gene
set 2, was used to compare the performance of our
method to a simple approach based on the number of
the gene-related publications, resulting from the search
keyword, for example, “pain” or “pain [MeSH]”, as well
as with other publicly available tools.
Gene set 1 was constructed from GO and MP data.
The relationship between the GO terms and genes were
obtained from the AmiGO website [17]. The relationship
between MP terms and genes were obtained from the
MGI website. Pain- or AD-related GO and MP terms,
which were manually selected by specialists in the fields
of pain or AD, are summarized in Tables 1 and 2. Gene
set 1 included 308 genes for pain (pain gene set 1), and
123 for AD (AD gene set 1). Gene set 2 for pain (pain
gene set 2) was constructed from the Pain Gene Data-
base. This set contained 369 unique, manually curated
genes as of September 2012. Gene set 2 for AD (AD
gene set 2) was constructed from OMIM (#104300) and
KEGG (hsa05010) databases. This set contained 123
unique genes. These databases which were source of the
gene set 2 were used as the evaluation set in other stud-
ies for gene prioritization [18-20].GO:1990000 Amyloid fibril formation
b)
MP:0000604 Amyloidosis
MP:0008493 Alpha-synuclein inclusion body
MP:0003214 Neurofibrillary tangles
MP:0004250 Tau protein depositsOverview of the method for the gathering and
prioritizing of disease candidate genes
The overall architecture of our method for the gathering
and prioritizing of each gene is shown in Figure 1. We
first optimized the search keywords for the comprehen-
sive retrieval of the publications related to disease
candidate gene. We calculated the occurrence similarity
between the MeSH term “disease name”, such as “pain”
or “Alzheimer’s disease”, and other MeSH terms to re-
trieve the MeSH terms related MeSH terms “disease
name” which were defined as “disease-related MeSH
terms”. Then we retrieved publications using disease-
related MeSH terms from PubMed. The relationships
between these publications and genes were obtained
from the gene2pubmed database. Finally, a prioritizing
score was calculated from the occurrence-based litera-
ture score to predict the gene most likely to be related
to the disease. The following sections describe the
methods in more detail.Figure 1 Flowchart of the method for gathering and prioritizing
pain candidate genes. We initially created a set of MeSH terms for
comprehensive retrieval of disease-related publications (left). Next,
specific disease candidate genes were obtained from disease-related
publications, which were searched for with a set of disease-related
MeSH terms. Finally, the prioritizing score was calculated based on
the weighted literature score (right).Obtaining of the relationship between genes and
publications
The relationship between genes and publications was
collected with gene2pubmed databases. The gene2-
pubmed database contains curated associations between
the NCBI Gene and PubMed databases. Gene2pubmed
database links to publications for each gene and is not
limited to articles specifically addressing the function of
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resulting from a search for disease-related MeSH terms.
We investigated orthologous gene pairs using the
Homologene database [21] to unify the redundancy of
genes for multiple species. In this study, genes from hu-
man, mouse, and rat species were considered, because
the majority of studies in the field of pain and AD re-
search is conducted in these species.
Selection of disease-related MeSH terms
To achieve comprehensive retrieval of publications re-
lated to a disease candidate gene, we constructed an op-
timal set of MeSH terms by calculating the frequency of
co-occurrence between the MeSH terms for the disease
states of “pain” or “Alzheimer disease”, and other MeSH
terms.
The occurrence similarity between these terms in publi-
cations which were referred in the gene2pubmed database
was calculated using cosine similarity, Dice similarity,
Jaccard similarity, mutual information, and Simpson simi-
larity measures.
The cosine similarity measure was computed as
follows:
simcosine X;Yð Þ ¼ X∩Yj jﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Xj j Yj jp
The Dice similarity measure was computed as follows:
simDice X;Yð Þ ¼ 2 X∩Yj jXj j þ Yj j
The Jaccard similarity measure was computed as





Pain C, F, G 1.000 x x x
Pain measurement E 0.340 x x
Nociceptors A 0.268 x
Pain threshold F, G 0.259
Hyperalgesia C 0.225
Posterior horn cells A 0.180
Ganglia, spinal A 0.147
Injections, spinal E 0.147
Physical stimulation E 0.146
Formaldehyde D 0.145
Recall 0.669 0.692 0.69simJaccard X;Yð Þ ¼ X∩Yj jX∪Yj j
The Simpson similarity measure was computed as
follows:
simSimpson X;Yð Þ ¼ X∩Yj jmin Xj j; Yj jð Þ
The point-wise mutual information measure was com-
puted as follows:
PMI X;Yð Þ ¼ logP X;Yð Þ
P Xð ÞP Yð Þ
Where |X| refers to the number of publications with
the MeSH term for the disease and |Y| refers to the
number of publications with another MeSH term. |X ∩
Y| refers to the number of publications with the MeSH
term for the disease co-occurring with another MeSH
term. P(X,Y) is the probability that X and Y elements ap-
pear at the same time. P(X) and P(Y) are the probabil-
ities of occurrence of each element.
We created multiple sets of MeSH terms, starting with
the most closely related terms and incrementally extend-
ing the list by one term. For example, using cosine simi-
larity analysis in the case study of pain, the first set
included MeSH terms “Pain” and “Pain Measurement”,
and the second set included MeSH terms “Pain”, “Pain
Measurement”, and “Nociceptors” (Table 3). We
searched PubMed using each set of MeSH terms, which
were combined with “OR” operators using the “[MeSH:
NoExp]” option.
The relationships between genes and publications were
obtained using the method previously described. The ac-
curacy of the obtained gene list was evaluated using re-
call at rank which was the number of genes obtained inbasis of the cosine similarity
MeSH term set
#3 #4 #5 #6 #7 #8 #9
x x x x x x x
x x x x x x x
x x x x x x x
x x x x x x x
x x x x x x
x x x x x




3 0.693 0.703 0.700 0.668 0.667 0.661 0.650
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“Alzheimer Disease [MeSH:NoExp]”. The set of MeSH
terms that achieved the highest recall was defined as the
set of “pain-related MeSH terms” or “AD-related MeSH
terms”.
Calculation of the prioritizing score
To prioritize the genes in the gene set, we introduced a
“weighted literature score”, which was based on the
number of the genes referred to by a publication. This
score depends on the assumption that if a publication re-
ferred to many genes, the degree of contribution to each
gene by that study is low. For example, publications de-
scribing microarray or genome sequencing studies refer to
many genes so we assumed that the contribution of these
publications to each gene was relatively minor. Therefore,
we defined the weighted literature score of gene i, which




f i; jð Þ  1 Pj
 
Where n refers to the total number of publications asso-
ciated with the gene2pubmed database, and Pj refers to
the number of genes associated with publication j. f(i, j) =
0 if gene i is not associated with publication j and f(i, j) = 1
if gene i is associated with publication j.
To assess the performance of this scoring method,
we compared it against three other well-known scoring
methods based on the number of gene-related publica-
tions. The measures used for comparison were the
number of publications, modified TF-IDF measure, and
p-value calculated with the hypergeometric distribution and
Benjamini-Hochberg false discovery rate correction [22].
The modified TF-IDF measure score of gene i was de-





f i; jð Þ  log n Li= Þð
Lj refers to the number of publication associated with
gene i.
The recall of each rank of genes from each scoring
method was calculated against gene set 1. The Wilcoxon
signed-rank test was used to calculate the statistical sig-
nificance of prioritization.
Performance assessment of gene prioritization
To assess the performance of gene prioritization, we cal-
culated the accumulated precision, recall, and F-measure
for the top n out of the total genes in the ranking. In this
approach, Tn represents the number of genes retrieved
by our method or other publicly available tools that havebeen extracted correctly in the top n genes, which were
included in gene set 2. C is the total number of genes in
gene set 1 or gene set 2. En is the number of genes ex-
tracted by our method or other publicly available tools
in the top n genes.
We defined recall, which was denoted as R(n), preci-
sion, which was denoted as P(n), and the F-measure (i.e.,
harmonic average of precision and recall), which was de-
noted as F(n) in the top n genes, based on the following
equations:
R nð Þ ¼ Tn
C
P nð Þ ¼ Tn
En
F nð Þ ¼ 2 R nð Þ P nð Þ
R nð Þ þ P nð Þ
The maximum F-measure was also used to compare
to performance of gene prioritization.
Comparing the performance against other keywords
We compared the performance of our method to a sim-
ple approach based on the ranking of the genes accord-
ing to the number of gene related publications, resulting
from the search term “pain” or “pain [MeSH]” in the
case study of pain. First, we retrieved publications from
PubMed using the keyword “pain” or “pain [MeSH]”.
Next, the relationships between these publications and
genes were obtained from the gene2pubmed database.
Then, a prioritizing score was calculated from the num-
ber the gene related publications. Finally, for each
method we compared the values of accumulated preci-
sion, recall, and maximum F-measure for the top n out
of the total genes in the ranking. We also conducted this
comparison for AD.
Comparing the performance against other publicly
available tools
We compared the performance of our method against
several publicly available tools which extract the general
gene-disease relationship by using various methods,
which are text mining and integration of multiple
data sources, in order to assess the effect of focusing
on pain field. PolySearch and LEGENDA extract know-
ledge data from the literature based on keyword co-
occurrence analysis and automatic extraction of entity
names from text. Genotator and Gene Prospector ex-
tract and prioritize candidate genes based on multiple
data sources.
The prioritization lists of pain or AD candidate genes
identified using other tools were compiled using queries
of the keyword “pain” or “Alzheimer’s disease”, and
AB
Figure 2 Comparison of prioritization score performance.
A) Pain case study B) AD case study.
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genes with the description “protein family or complex”
were excluded because it was not possible to determine
the relationships between genes and gene symbols
within the NCBI Gene database. As these tools are lim-
ited to human genes, orthologous information was in-
corporated by the Homologene database. We compared
the value of the accumulated precision, recall, and max-
imum F-measure for the top n out of the total genes in
the ranking.
Results
Case study 1: pain
Pain is a major healthcare issue as defined by the World
Health Organization and has complex pathophysiology
[23,24]. Especially, chronic pain has remained a major
healthcare issue affecting not only patients by decreasing
their quality of life but also society as a whole by increas-
ing socioeconomic costs. Unfortunately, many patho-
logical pain conditions remain poorly understood and
resist currently available treatment. Therefore, the devel-
opment of new therapeutic approaches to managing pain
will undoubtedly depend on a better understanding of the
molecular, cellular, and circuit mechanisms underlying
pain states.
In this study, genes related to primary disease, such as
diabetes mellitus, cancer, and infectious disease were not
considered.
Evaluation of scoring methods for gene prioritization
We initially evaluated the performance of scoring methods
for gene prioritization because we used the best scoring
method for constructing a set of pain-related MeSH
terms. A total of 690 genes were obtained from the publi-
cations searched using the keyword MeSH term “pain
[Mesh:NoExp]” in PubMed. The prioritization scores of
these genes were calculated using four methods and the
recall of each method is shown in Figure 2A. The
weighted literature score produced the best performance
(p < .05). The higher ranked genes were predicted accur-
ately with each method. The weighted literature score
achieved better prediction accuracy at the low ranking
area than other methods.
Therefore, for subsequent analyses, the weighted lit-
erature score was applied for prioritization.
Selection of pain-related MeSH terms
Figure 3 shows the recall of the genes obtained from
publications retrieved from searches for each set of
MeSH terms created by the various similarity measures.
The highest recall (0.703) was achieved using MeSH
term set 4 which was constructed using MeSH term
similarity, which was calculated by the cosine, Dice, and
Jaccard measures against pain gene set 1. This setcomprised the combination of the MeSH terms “pain”,
“pain measurement”, “nociceptor”, “pain threshold”, and
“hyperalgesia”. These five MeSH terms were defined as
pain-related MeSH terms.
Table 3 shows that the example of MeSH terms with a
high occurrence similarity with the MeSH term “pain”
calculated by the cosine similarity and the recall of gath-
ering genes. MeSH terms with close cosine distance to
the MeSH term “pain” belonged to various categories of
MeSH tree structures (Table 3). Some of these categories
are different from the categories that the MeSH term
“pain” belongs to, which are “C” (Disease), “F” (Psychiatry
and Psychology), and “G” (Phenomena and Processes).
The MeSH term with the closest cosine distance value
(0.34) was “Pain Measurement” which belongs to category
“E” (Analytical, Diagnostic, and Therapeutic Techniques
and Equipment). The term with the second closest cosine
distance value (0.268) was “Nociceptors” which belongs to
category “A” (Anatomy).
Gathering and prioritizing the pain candidate genes
To assess the performance of our method, precision and
recall were compared at each gene rank for three gene sets
against pain gene set 2. These sets were created using pub-
lications resulting from searches for pain-related MeSH
terms, “pain” and “pain [MeSH]” in Pubmed.
The precision-recall curves for each set are presented
in Figure 4. Our method achieved a precision value of
0.30 and a recall value of 0.89 for 1101 genes. The preci-
sion and recall values for 2059 genes from simple ap-
proach based on the ranking of the genes by the number
AB
Figure 3 Summary of the recall of prioritized genes resulting from each set of MeSH terms constructed using various similarity
measures. A) Recall was calculated against pain gene set 1. “Pain” is located in the leftmost means the recall of the list of genes constructed by
searching for the keyword “pain [Mesh:NoExp]” B) The recall was calculated against AD gene set 1. “Alzheimer Disease” is located in the leftmost
means the recall of the list of genes obtained by searching for the keyword “Alzheimer Disease [Mesh:NoExp]”. The red bars indicate the set of
MeSH terms with the highest recall.
Figure 4 Comparison of pain candidate gene prioritization
performance. Precision-recall plots show the performance of our
method and of a simple approach based on the ranking of genes
according to the number of gene related publications, resulting
from the search term “pain” or “pain [MeSH]”.
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0.17 and 0.93, respectively, whereas the precision and re-
call values for 1172 genes from simple approach with
the keyword “pain [MeSH]” were 0.27 and 0.84, respect-
ively. The maximum F-measures for pain-related MeSH
terms, “pain” and “pain [MeSH]” were 0.61, 0.48, and
0.51 with gene ranks of 381, 624, and 518, respectively.
We found the performance of our method to be superior
to alternative simple methods, with a higher precision-
recall curve across the entire range.
The top 20 ranked genes from our method are summa-
rized in Table 4 (all genes are summarized in Additional
file 1). The top ranked gene was TRPV1 (WLS = 140.92),
and the second ranked gene was Oprm1 (WLS = 81.89).
Both are well-known targets of analgesic drugs, such as
capsaicin patch and morphine. Other high-ranked genes
presented in Table 4 also had well-known associations with
pain disease because 19 of the 20 genes were included in
Table 4 The top-20 ranked pain candidate genes
gathered by our method
Score Gene Description
140.92 Trpv1 Transient receptor potential cation channel,
subfamily V, member 1
81.89 Oprm1 Opioid receptor, mu 1
55.04 Trpa1 Transient receptor potential cation channel,
subfamily A, member 1
39.56 Tacr1 Tachykinin receptor 1
38.78 Comt Catechol-O-methyltransferase
31.04 P2rx3 Purinergic receptor P2X, ligand-gated ion channel, 3
30.96 Bdnf Brain-derived neurotrophic factor
27.58 Scn9a Sodium channel, voltage-gated, type IX, alpha
27.48 Ptgs2 Prostaglandin-endoperoxide synthase 2
26.33 Cnr1 Cannabinoid receptor 1 (brain)
23.67 Ngf Nerve growth factor (beta polypeptide)
23.49 Tnf Tumor necrosis factor
23.3 Asic3 Acid-sensing (proton-gated) ion channel 3
23.09 Scn10a Sodium channel, voltage-gated, type X, alpha subunit
22.97 Tac1 Tachykinin, precursor 1
20.58 Fos FBJ osteosarcoma oncogene
19.83 Gal Galanin/GMAP prepropeptide
19.72 Calca Calcitonin-related polypeptide alpha
19.41 Il6 Interleukin 6
19.06 Grin1 Glutamate receptor, ionotropic, N-methyl D-aspartate 1
Figure 5 Comparison of pain candidate gene prioritization
performance with other publicly available tools. Precision-recall
plots show the performance of our method and of other publicly
available tools. The precision and recall of other publicly available
tools were calculated by the number of genes resulting from the
use of the keyword “pain” using default parameters.
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base was the FBJ osteosarcoma oncogene, ranked at 16.
Comparison with other tools
We compared our method against other publicly avail-
able tools using the pain gene set 2 and found the per-
formance of our method to be superior, with a higher
precision-recall curve across the entire range (Figure 5).
Additionally, the maximum F-measure of our method
was 0.61 which was higher than the other publicly avail-
able tools (Table 5); these had values of 0.23 (Genotator),
0.26 (Gene Prospector), 0.19 (LEGENDA), and 0.14
(PolySearch).
One-hundred and sixty of 381 genes which were the
number of genes at the rank of maximum F-measure
were not extracted by other publicly available tools. Of
these 160 genes, 94 were included in the pain gene set 2
(see Additional file 2). Acid-sensing ion channel 3
(ASIC3) which ranked at 13 (Table 4) is a typical ex-
ample. ASIC3 is the most sensitive acid sensor in sen-
sory neurons, and secondary mechanical hyperalgesia is
not observed in knockout mice for this gene [25]. This
channel is critical for the development of secondary
hyperalgesia as measured by mechanical stimulation of
the paw following muscle insult. Another example is thegene encoding L1 cell adhesion molecule, which was
also identified solely by our method (ranked at 162,
Additional file 1). This gene encodes a cell adhesion mol-
ecule that contributes to axonal outgrowth, guidance, and
fasciculation in development, in addition to synapse for-
mation and plasticity. This gene plays a role in the main-
tenance of thermal hyperalgesia following spinal cord
injury in mice [26]. These results suggest that our method
is more effective for the comprehensive gathering of pain
candidate genes than publicly available tools.Case 2: Alzheimer’s disease
In order to evaluate the application of this method to
other diseases, we conducted a gene search for AD.
There is a clear and significant need for better therapy
for AD. It is critical to understand the underlying mo-
lecular mechanism of AD for the development of novel
treatments.Evaluation of scoring methods for gene prioritization
We evaluated the performance of scoring methods for
gene prioritization for AD as we did in the case of pain.
A total of 2178 genes were obtained from publications re-
trieved from a search using the MeSH term “Alzheimer
Disease [Mesh:NoExp]” in PubMed. The prioritization
scores of these genes were calculated using four methods.
The recall of each method is shown in Figure 2B. The
weighted literature score produced the best performance
(p < .05). The higher ranked genes were predicted accur-
ately with each method. The weighted literature score
achieved better prediction accuracy with low ranking
genes than that of other methods.
Table 5 Summary of the maximum F-measures for pain








Our method 1101 0.61 381
Genotator 892 0.23 544
Gene prospector 603 0.26 278
LEGENDA 601 0.19 601
PolySerach 83 0.14 83
Table 6 The top-20 ranked AD candidate genes gathered
by our method
Score Gene Description
1477.54 App Amyloid beta (A4) precursor protein
1469.69 Apoe Apolipoprotein E
794.48 Mapt Microtubule-associated protein tau
560.37 Psen1 Presenilin 1
150.82 Bace1 Beta-site APP cleaving enzyme 1
105.30 Psen2 Presenilin 2
66.48 Snca Synuclein, alpha (non A4 component of
amyloid precursor)
62.84 Gsk3b Glycogen synthase kinase 3 beta
58.73 Prnp Prion protein
52.96 Bdnf Brain-derived neurotrophic factor
46.54 Aplp2 Amyloid beta (A4) precursor-like protein 2
45.49 Serpine2 Serpin peptidase inhibitor, clade E
(nexin, plasminogen activator inhibitor type 1),
member 2
43.20 Mme Membrane metallo-endopeptidase
39.21 Ide Insulin degrading enzyme
38.82 Ncstn Nicastrin
37.61 Cdk5 Cyclin-dependent kinase 5
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Figure 3 shows the recall of genes obtained from publi-
cations retrieved from searches for each set of MeSH
terms using various similarity measures. The highest re-
call (0.886) was achieved using MeSH term set 6, which
was constructed using MeSH term similarity calculated
by the cosine similarity measure. This set comprised the
combination of the MeSH terms “Alzheimer Disease”,
“Amyloid beta-Peptides”, “Amyloid beta-Protein Precur-
sor”, “Presenilin-1”, “Apolipoprotein E4”, “Plaque, Amyl-
oid”, and “tau Proteins”. These seven MeSH terms were
defined as AD-related MeSH terms.37.08 Sorl1 Sortilin-related receptor, LDLR class A
repeats-containing
36.96 Ace Angiotensin I converting enzyme
35.06 Apbb1 Amyloid beta (A4) precursor protein-binding,
family B, member 1 (Fe65)
32.46 Clu ClusterinGathering and prioritizing AD candidate genes
To assess the performance of our method, precision and
recall for three gene sets were compared with AD gene
set 2 at each gene rank. These sets were created using
publications resulting from searches for AD-related
MeSH terms, “Alzheimer’s disease” and “Alzheimer dis-
ease [MeSH]” in Pubmed.
Our method achieved a precision value of 0.04 and a
recall value of 0.60 for 2810 genes. The top 20 ranked
genes from our method are summarized in Table 6.
The precision and recall values for 2940 genes from sim-
ple approach based on the ranking of the genes by the
number of times the gene appears with keyword “Alzhei-
mer’s Disease” were 0.04 and 0.63, respectively, whereas
the precision and recall values for 2178 genes from simple
approach with using the keyword “Alzheimer’s Disease
[MeSH]” were 0.04 and 0.53, respectively. The maximum
F-measures for AD-related MeSH terms, “Alzheimer’s
Disease” and “Alzheimer Disease [MeSH]” were 0.24, 0.22,
and 0.23 with gene ranks of 166, 134, and 194, respectively.Comparison with other tools
We also compared our method against other publicly
available tools using AD gene set 2 and found the per-
formance of our method to be superior (Figure 6).
Additionally, the maximum F-measure of our method
was 0.24, which was higher than other publicly available
tools (Table 7). The publicly available tools had valuesof 0.15 (Genotator), 0.16 (Gene Prospector), 0.14
(LEGENDA), and 0.12 (PolySearch).
Two of 166 genes which were the number of genes at
the rank of maximum F-measure were not extracted by
other publicly available tools and were not included in
AD gene set 2. These two genes were chemokine (C-X3-
C motif ) receptor 1 (CX3CR1) and Bcl2-associated X
protein (BAX). Nonetheless, there are publications that
provide evidence for an association between these genes
and AD. CX3CR1, which ranked 132, is a key microglial
pathway in protecting against AD-related cognitive defi-
cits that are associated with aberrant microglial activa-
tion and elevated inflammatory cytokines [27]. BAX,
which ranked 164, plays a role in neuronal cell death.
Importantly, expression levels of these proteins are re-
portedly altered in vulnerable neurons in AD. The inhib-
ition of Bax activity using either Bax-inhibiting peptide
or Bax gene knockout significantly prevented oligomeric
amyloid beta-induced neuronal cell death [28].
Discussion
While several attempts have been made to develop
methods for extracting and prioritizing disease candidate
Figure 6 Comparison of AD candidate gene prioritization performance with other publicly available tools. Precision-recall plots show the
performance of our method and of other publicly available tools. The precision and recall of other publicly available tools were calculated by the
number of genes resulting from the use of the keyword “Alzheimer’s disease” using default parameters.
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for the inference of specific disease-relevant genes, such
as pain or AD, has not yet been developed [10]. In this
study, we developed computational methods to gather
and prioritize the most likely candidate genes associated
with specific disease. The features of our method include
creating a set of disease related MeSH terms for the
comprehensive retrieval of disease candidate gene re-
lated publications, and developing a novel prioritization
score for improving ranking accuracy. The relationships
between genes and publications were correctly obtained
using the gene2pubmed database. There are other
sources to find relationships between genes and publica-
tions such as Gene Reference Into Function (GeneRIF),
which uses the gene-disease relation extraction system
[29]. GeneRIF is a database in which human experts
provide a brief summary of gene functions and make
the connections between citations (PubMed) and NCBI
Gene databases [30]. Although we used this index to ob-
tain a relationship between genes and publications, we
could not obtain a good performance (data not shown).Table 7 Summary of the maximum F-measures for AD








Our method 2810 0.24 166
Genotator 2110 0.15 145
Gene prospector 1587 0.16 216
LEGENDA 1440 0.14 142
PolySearch 180 0.12 101Many methods for extracting knowledge from the litera-
ture using text mining are based on co-occurrence ana-
lysis of given keywords, which automatically extracts
entity names from the text. However, automatic entity
name recognition methods often incorrectly identify a
significant portion of genes mentioned within the text
[31,32] and consequently introduce noise and ambiguity
into the extraction method. For example, in the case
study of pain, the word TENS was recognized as a gene
name by PolySearch and LEGENDA. However, in the
field of pain research, TENS is usually used as an abbre-
viation for “transcutaneous electrical nerve stimulation”,
a therapeutic strategy. To avoid this problem, our
method used the gene2pubmed database which contains
a list of associations between PubMed IDs and unam-
biguous gene identifiers.
By focusing on specific disease, we assembled disease-
related MeSH terms to improve information retrieval
from PubMed. In the case study of pain, a best set
of MeSH terms, including “pain”, “pain measurement”,
“nociceptor”, “pain threshold”, and “hyperalgesia”, was
selected with the highest recall for pain gene set 1. Re-
call was reduced when MeSH terms (excluding pain-
related MeSH terms) which appeared as frequently as
“pain” (i.e., “posterior horn cells”, “ganglia, spinal”, “in-
jections, spinal”, “physical stimulation”, and “formalde-
hyde”), were added to the set in the case of cosine
similarity measure. This may be because these terms do
not have a specific meaning for pain disease. “Posterior
horn cells” and “ganglia, spinal” refer to tissue, while “in-
jections, spinal” and “physical stimulation” refer to gen-
eral methods, and “formaldehyde” identifies the general
reagent. So, the genes that were not related to pain were
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MeSH terms belong to various MeSH categories, com-
prehensive gathering was achieved, which could not be
accomplished by searching only the MeSH term “pain”.
The example is the gene that encodes reticulon 4 (Rtn4),
which was referenced in publications by the MeSH term
“pain measurement”. This gene was assigned to GO term
“GO: 0051930 regulation of sensory perception of pain”.
The related publication indicated that Nogo-66, the 66-
residue domain of Rtn4, may be related to a reduction in
neuropathic pain following periphery nerve injury [33].
In the top-ranked 381 genes, 94 genes were not ex-
tracted by the other publicly available tools from the
pain gene set 2; in addition, 121 pain candidate genes
were not included in both pain gene set 1 and 2. An ex-
ample of these 121 genes is FBJ murine osteosarcoma
viral oncogene homolog (FOS) which ranked at 16, this
has been extensively used as a marker for the activation
of nociceptive neurons in the spinal cord [34]. The de-
gree of spinal c-Fos expression was correlated with the ex-
tent of the pain-related behavior of carrageenan-injected
rats [35]. Another example is sphingosine-1-phosphate re-
ceptor 1 gene (S1PR1) which ranked at 196. Sphingosine-
1-phosphate (S1P) is a key regulator of the immune
response. S1P- and inflammation-induced hypersensitivity
is significantly reduced in mice with a conditional
nociceptor-specific deletion in S1PR1 [36]. Thus, S1P/
S1PR1 signaling may be a key player in the onset of
thermal hypersensitivity and hyperalgesia. These results
suggest that our method was very effective for the com-
prehensive gathering of pain candidate genes.
To achieve high prioritization accuracy, we defined a
weighted literature score. Several conventional methods
have been used to calculate the co-occurrence frequency
and appearance for the prioritization of each gene. Other
text mining methods use the statistical p-value calcu-
lated from the number of publications [18]. However,
the prioritization scores from these methods are likely to
be overestimated, because several publications related to
–omics analysis, such as microarray and genome se-
quence analysis, may cite many genes. We hypothesized
that the contribution of these studies to each gene is
relatively minor, and developed the weighted literature
score to account for the number of genes studied in a
given publication. The results of our study indicate that
weighted literature scores improved performance com-
pared with other scoring methods.
The results of our AD case study illustrate the applic-
ability of our method to other diseases. However, the
limitation is the lack of comprehensive applicability to
other diseases. Disease-specific systems are able to
exploit domain knowledge more thoroughly and thus
achieve higher accuracy than general purpose systems,
but the utility of these systems is not portable [37]. Ourmethod is a semi-automated method for which a special-
ist’s knowledge is needed for GO and MP term selection.
It is expected that adaptation to other diseases can also
be promoted in the future if the retrieval of disease
specific MeSH terms can be performed efficiently and
automatically.
Another limitation of our method is that it will not
discover novel disease candidate genes that are not cited
in the disease-related literature. This includes studies
that are newly registered in PubMed for which there
would be no gene-PubMed ID relationship in GeneRIF
or gene2pubmed and no MeSH term information. How-
ever, the accumulation of precise information from the
literature by using our method may help to advance our
understanding of disease mechanisms. It may also lead
to the generation of novel hypotheses for understanding
molecular mechanisms involved in disease when used in
combination with further analyses such as network
analysis [38]. We believe that our method for the com-
prehensive retrieval of disease candidate genes from
the literature is a useful step toward understanding the
mechanisms of disease.
Conclusions
Our method, which involves the use of a set of disease-
related MeSH terms and a weighted literature score,
showed better performance than did other publicly avail-
able tools that extract general gene-disease associations.
The gene list obtained with our method would be
beneficial for the study of disease mechanisms and
would also provide a source of potential disease bio-
markers and potential targets for novel therapies.
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